Travere Therapeutics Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Travere Therapeutics is gedaald met een gemiddeld jaarlijks percentage van -25.6%, terwijl de winst van de Biotechs -industrie jaarlijks groeide met 19.1%. De inkomsten zijn daalde met een gemiddeld percentage van 5.5% per jaar.

Belangrijke informatie

-25.6%

Groei van de winst

-14.2%

Groei van de winst per aandeel

Biotechs Groei van de industrie	17.0%
Inkomstengroei	-5.5%
Rendement op eigen vermogen	n/a
Nettomarge	-171.5%
Laatste winstupdate	30 Sep 2024

Recente prestatie-updates uit het verleden

Recent updates

Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shares Bounce 27% But Its Business Still Trails The Industry

Oct 31

Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

Oct 07

Travere Therapeutics Faces Challenges But Holds Promise With Filspari Beyond IgAN

Sep 30

Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too

Sep 10

Travere Therapeutics: Judgement Day Is Nigh For Sparsentan

Aug 30

Shareholders May Be More Conservative With Travere Therapeutics, Inc.'s (NASDAQ:TVTX) CEO Compensation For Now

May 02

Lacklustre Performance Is Driving Travere Therapeutics, Inc.'s (NASDAQ:TVTX) 29% Price Drop

Apr 20

Travere Therapeutics: Restructuring Away From Disaster

Jan 30

Travere Therapeutics (NASDAQ:TVTX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Jan 22

Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 48% But Its Business Prospects Need A Lift Too

Dec 18

New Forecasts: Here's What Analysts Think The Future Holds For Travere Therapeutics, Inc. (NASDAQ:TVTX)

Aug 08

Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

Jun 09

It's Down 27% But Travere Therapeutics, Inc. (NASDAQ:TVTX) Could Be Riskier Than It Looks

May 05

Travere Therapeutics GAAP EPS of -$1.05 misses by $0.14, revenue of $54.2M beats by $4.7M

Aug 04

Travere Theraspeutics a new buy at Canaccord as a 'rare disease powerhouse'

Jul 14

Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?

Jun 19

Opbrengsten en kosten

Hoe Travere Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGM:TVTX Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 24	203	-349	258	0
30 Jun 24	178	-383	260	0
31 Mar 24	156	-416	264	65
31 Dec 23	145	-376	266	0
30 Sep 23	130	-373	259	0
30 Jun 23	120	-368	244	0
31 Mar 23	92	-352	217	0
31 Dec 22	109	-331	198	0
30 Sep 22	137	-297	183	0
30 Jun 22	178	-249	166	0
31 Mar 22	229	-202	160	0
31 Dec 21	132	-217	126	0
30 Sep 21	221	-250	144	-93
30 Jun 21	204	-237	139	-61
31 Mar 21	198	-224	139	-30
31 Dec 20	198	-169	136	0
30 Sep 20	194	-78	128	130
30 Jun 20	187	-92	125	131
31 Mar 20	184	-105	129	138
31 Dec 19	175	-146	129	0
30 Sep 19	172	-124	127	137
30 Jun 19	169	-142	124	136
31 Mar 19	165	-125	110	133
31 Dec 18	164	-103	104	124
30 Sep 18	163	-113	104	111
30 Jun 18	162	-76	101	97
31 Mar 18	160	-67	105	82
31 Dec 17	155	-60	101	78
30 Sep 17	150	-51	101	79
30 Jun 17	144	-70	102	79
31 Mar 17	138	-70	96	77
31 Dec 16	134	-48	92	71
30 Sep 16	127	-42	88	66
30 Jun 16	121	101	87	62
31 Mar 16	112	89	84	55
31 Dec 15	100	117	80	50
30 Sep 15	84	91	69	50
30 Jun 15	64	-33	64	48
31 Mar 15	46	4	53	51
31 Dec 14	28	-111	59	48
30 Sep 14	14	-95	49	38
30 Jun 14	6	-89	36	27
31 Mar 14	0	-105	31	14

Kwaliteitswinsten: TVTX is momenteel verliesgevend.

Groeiende winstmarge: TVTX is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: TVTX is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 25.6% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van TVTX over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: TVTX is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( 16.6% ).

Rendement op eigen vermogen

Hoge ROE: De schulden van TVTX zijn groter dan de activa, dus het is lastig om het rendement op het eigen vermogen te berekenen.

Travere Therapeutics Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Travere Therapeutics, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Travere Therapeutics, Inc. to Report Q2, 2024 Results on Aug 01, 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Travere Therapeutics, Inc. to Report Q1, 2024 Results on May 06, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Travere Therapeutics, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Recent updates

Travere Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

Travere Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shares Bounce 27% But Its Business Still Trails The Industry

Travere Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Travere Therapeutics, Inc. to Report Q3, 2024 Results on Oct 31, 2024

CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy

Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

Travere Therapeutics Faces Challenges But Holds Promise With Filspari Beyond IgAN

Travere Therapeutics, Inc. Announces Voluntary Pause of Enrollment in the Phase 3 Harmony Study of Pegtibatinase related to Commercial Manufacturing Scale-Up

Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too

Travere Therapeutics: Judgement Day Is Nigh For Sparsentan

Travere Therapeutics, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Forecast to breakeven in 2026

Consensus EPS estimates fall by 13%, revenue upgraded

New minor risk - Profitability

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Forecast to breakeven in 2026

Shareholders May Be More Conservative With Travere Therapeutics, Inc.'s (NASDAQ:TVTX) CEO Compensation For Now

Travere Therapeutics, Inc. to Report Q1, 2024 Results on May 06, 2024

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

Lacklustre Performance Is Driving Travere Therapeutics, Inc.'s (NASDAQ:TVTX) 29% Price Drop

Travere Therapeutics to Present Abstracts on Filspari® (Sparsentan) in Iga Nephropathy At World Congress of Nephrology and the American Nephrology Nurses Association

Travere Therapeutics, Inc., Annual General Meeting, May 08, 2024

Travere Therapeutics, Inc. Submits Supplemental New Drug Application to U.S. Food and Drug Administration Seeking Full Approval of FILSPARI (Sparsentan) for Treatment of IgA Nephropathy

Travere Therapeutics, Inc. and Csl Vifor Announce Sparsentan Receives Positive Chmp Opinion for the Treatment of Iga Nephropathy

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates upgraded to US$1.86 loss

Travere Therapeutics, Inc. to Report Q4, 2023 Results on Feb 15, 2024

President recently sold US$78k worth of stock

President notifies of intention to sell stock

Travere Therapeutics: Restructuring Away From Disaster

Travere Therapeutics (NASDAQ:TVTX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Travere Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023

Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 48% But Its Business Prospects Need A Lift Too

Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU)

Consensus EPS estimates fall by 35%

Travere Therapeutics, Inc. Completes Successful Pre-NDA Meeting for FILSPARI in IgAN

Consensus EPS estimates upgraded to US$1.55 loss

Consensus revenue estimates decrease by 16%, EPS upgraded

New major risk - Share price stability

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Travere Therapeutics, Inc. Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and Fs Published in the Lancet and the NEJM Respectively and Presented At the American Society of Nephrology Kidney Week 2023

Travere Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Travere Therapeutics Announces Confirmatory Data from the Phase 3 Protect Study of Filspari Demonstrating Long-Term Kidney Function Preservation in Iga Nephropathy; Narrowly Missing Egfr Total Slope Endpoint Versus Active Control, Irbesartan

Price target decreased by 17% to US$22.40

Mirum Pharmaceuticals, Inc. (NasdaqGM:MIRM) completed the acquisition of Bile Acid Product Portfolio from Travere Therapeutics, Inc. (NasdaqGM:TVTX).

Mirum Pharmaceuticals, Inc. (NasdaqGM:MIRM) completed the acquisition of Bile Acid Product Portfolio from Travere Therapeutics, Inc. (NasdaqGM:TVTX).

Consensus revenue estimates increase by 10%

New Forecasts: Here's What Analysts Think The Future Holds For Travere Therapeutics, Inc. (NASDAQ:TVTX)

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Travere Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

Travere Therapeutics, Inc. Announces Positive Topline Results from Cohort 6 in the Phase 1/2 Compose Study of Pegtibatinase in Classical Homocystinuria

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

It's Down 27% But Travere Therapeutics, Inc. (NASDAQ:TVTX) Could Be Riskier Than It Looks

Price target decreased by 17% to US$29.33

Insufficient new directors

Consensus EPS estimates fall by 16%

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Price target increased by 7.2% to US$35.83

Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI(sparsentan), the First and Only Non-Immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy

Travere Therapeutics, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

President notifies of intention to sell stock

Travere Therapeutics, Inc. Provides Financial Guidance for the Fourth Quarter and for the Fiscal Year 2022

President notifies of intention to sell stock

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Travere Therapeutics, Inc. to Report Q3, 2022 Results on Oct 27, 2022

Price target decreased to US$33.90